Screener
Ligand Pharmaceuticals LGND Q1 2026 earnings
Reported May 14, 2026 · Before market open
Revenue$51.7MMiss by $7.4M
EPS$1.63Miss by $0.21
Revenue estimate$59.1M
EPS estimate$1.84
Next report
Nov 5, 2026 (in 2 months)Revenue estimate$78.1M
EPS estimate$2.30
Valuation & ratios
Segments
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Ligand Pharmaceuticals report Q1 2026 earnings?
- Ligand Pharmaceuticals (LGND) reported Q1 2026 earnings on May 14, 2026 before market open.
- What were Ligand Pharmaceuticals's Q1 2026 revenue and EPS?
- Ligand Pharmaceuticals reported revenue of $51.7M and eps of $1.63 for Q1 2026.
- Did Ligand Pharmaceuticals beat estimates in Q1 2026?
- Revenue missed the consensus estimate of $59.1M by $7.4M. EPS missed the consensus estimate of $1.84 by $0.21.
- How did Ligand Pharmaceuticals's Q1 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 14.1% from $45.3M a year earlier and eps grew 22.6% from $1.33.
- Where can I find Ligand Pharmaceuticals's Q1 2026 SEC filings?
- You can read the 10-Q periodic report (0000886163-26-000034) directly on SEC EDGAR. The filing index links above go to sec.gov.
